Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Teratogenic Risk Impact and Mitigation (TRIM): Study Protocol for the Development of a Decision Support Tool to Prioritize Medications for Risk Mitigation.
Winterstein AG, Ewig CLY, Wang Y, Smolinski NE, Toyserkani GA, LaCivita C, Lackey L, Eggers S, Zhou EH, Diaby V, Sarayani A, Thai T, Maro JC, Rasmussen SA. Winterstein AG, et al. Among authors: toyserkani ga. Drug Saf. 2024 Nov 5. doi: 10.1007/s40264-024-01488-4. Online ahead of print. Drug Saf. 2024. PMID: 39499480
Removing the FDA's Boxed Hepatotoxicity Warning and Liver Function Testing Requirement for Ambrisentan.
Feldman WB, Mahesri M, Sarpatwari A, Huybrechts KF, Zhu Y, Hwang CS, Lii J, Lee SB, Kattinakere Sreedhara S, Toyserkani GA, Zhou EH, Zendel L, LaCivita C, Manzo C, Dal Pan GJ, Kesselheim AS, Bykov K. Feldman WB, et al. Among authors: toyserkani ga. JAMA Netw Open. 2024 Jul 1;7(7):e2419873. doi: 10.1001/jamanetworkopen.2024.19873. JAMA Netw Open. 2024. PMID: 39023895 Free PMC article.
Trends in Use and Evidence of Adherence to Risk Evaluation and Mitigation Strategy Pregnancy Testing Requirements for Thalidomide, Lenalidomide, and Pomalidomide in the USA, 2000-2020.
Mahesri M, Sarpatwari A, Huybrechts KF, Lii J, Lee SB, Toyserkani GA, LaCivita C, Zhou EH, Dal Pan GJ, Kesselheim AS, Bykov K. Mahesri M, et al. Among authors: toyserkani ga. Drug Saf. 2024 Sep;47(9):909-919. doi: 10.1007/s40264-024-01443-3. Epub 2024 May 16. Drug Saf. 2024. PMID: 38755509
A Multi-modal Approach to Evaluate the Impact of Risk Evaluation and Mitigation Strategy (REMS) Programs.
Sarpatwari A, Mitra-Majumdar M, Bykov K, Avorn J, Woloshin S, Toyserkani GA, LaCivita C, Manzo C, Zhou EH, Pinnow E, Dal Pan GJ, Gagne JJ, Huybrechts KF, Feldman WB, Chin K, Kesselheim AS. Sarpatwari A, et al. Among authors: toyserkani ga. Drug Saf. 2021 Jul;44(7):743-751. doi: 10.1007/s40264-021-01070-2. Epub 2021 Apr 27. Drug Saf. 2021. PMID: 33904111